Table 3 Posaconazole
From: Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
Overall (n = 100) |  |  |  |
|---|---|---|---|
Drug concentration (μg/ml) (Median [IQR]) |  | 1.26 (0.50–1.91) |  |
Comparison | Therapeutic drug level (n = 69) | Non-therapeutic drug level (n = 31) | p |
PK parameters | |||
 Drug concentration (μg/ml) (median [IQR]) | 1.61 (1.17–2.30) | 0.19 (0.15–0.48) | <0.01 |
 Total daily dose (mg) (median [IQR]) | 300 (300–400) | 800 (600–1200) | <0.01 |
 mg/kg/dose (median [IQR]) | 4.03 (3.3–4.9) | 4.08 (2.5–5.5) | 0.75 |
 mg/kg/day (median [IQR]) | 4.68 (3.8–7.5) | 9.67 (5.5–13.9) | <0.01 |
 Weight (median [IQR]) | 72 (55.3–80.0) | 77 (64.0–88.6) | 0.05 |
 Concomitant interacting medication | 13 (19) | 8 (26) | 0.44 |
PK parameters—initial dose only | (n = 21) | (n = 17) |  |
 mg/kg/dose (median [IQR]) | 4.16 (3.6–5.2) | 4.38 (2.5–5.4) | 0.54 |
 mg/kg/day (median [IQR]) | 5.67 (4.0–9.6) | 10.49 (5.4–14.4) | 0.04 |
 Weight (median [IQR]) | 74 (59.0–84.5) | 77 (64.0–87.7) | 0.36 |
Patient characteristics | |||
 Critically ill | 34 (49) | 16 (52) | 1.00 |
 Solid organ transplant recipients | 17 (25) | 4 (13) | 0.29 |
 Bone marrow transplant recipients | 14 (20) | 12 (39) | 0.08 |
 Cystic fibrosis | 1 (1) | 1 (3) | 0.53 |
 Immunocompromiseda | 41 (59) | 25 (81) | 0.04 |
Outcomes | |||
 Length of stay (days) (median [IQR]) | 27 (17–48) | 43 (36-76) | <0.01 |
 Treatment failure | 13 (18) | 9 (30) | 0.30 |
Comparison by patient | Therapeutic mean drug level (n = 22) | Non-therapeutic mean drug level (n = 16) |  |
|---|---|---|---|
Outcomes | |||
 Survive to hospital discharge (n = 38) | 14 (64) | 12 (75) | 0.50 |
 Treatment failure | 4 (18) | 3 (18) | 1.00 |
 Length of stay (days) (median [IQR]) | 23 (8–36) | 40 (35–57) | <0.01 |